Healthcare Equipment and Supplies
Company Overview of Ventana Medical Systems, Inc.
Ventana Medical Systems Inc. develops, manufactures, and markets instrument-reagent systems that automate slide staining. Its clinical systems are used in anatomical pathology labs in analyzing human tissue to assist in diagnosing and treating cancer and infectious diseases. Ventana’s drug-discovery systems are used by pharmaceutical and biotech companies to increase the discovery of new drug targets and to evaluate the safety of new compounds. It also markets consumable products, including reagents and other accessories, and serves hospital-based anatomical pathology labs, independent reference labs, government labs, medical research centers, and resellers serving these entities. Ventana Me...
1910 East Innovation Park Drive
Tucson, AZ 85755
Founded in 1985
Key Executives for Ventana Medical Systems, Inc.
Chief Executive Officer and Director
Founder, Chairman Emeritus, Chief Scientific Officer and Chief Medical Officer
Chief Financial Officer and Senior Vice President
Compensation as of Fiscal Year 2015.
Ventana Medical Systems, Inc. Key Developments
Ventana Medical Systems, Inc. Receives FDA Approval for ALK (D5F3) CDx Assay to Identify Lung Cancer Patients Eligible for Xalkori
Jun 15 15
Ventana Medical Systems, Inc. announced approval of the VENTANA ALK (D5F3) CDx Assay by the US Food and Drug Administration (FDA) as a companion diagnostic to aid in the identification of patients for Pfizer's FDA approved targeted therapy, XALKORI® (crizotinib). The VENTANA ALK Assay was approved as a CE-IVD in Europe in 2012 and was approved by the Chinese Food and Drug Administration (CFDA) in 2013. With this US FDA Class III approval, ALK IHC testing is now widely accessible on VENTANA BenchMark1 immunohistochemistry (IHC) instruments globally, can be easily integrated into standard lab workflow and offers fast test results with a binary, straightforward scoring method. The test provides physicians and patients a fast and accurate method to identify ALK protein expression, and clinicians can be confident knowing that the company's FDA approval is based on data resulting from collaboration between Ventana and Pfizer. The company used the VENTANA ALK (D5F3) CDx assay and scoring method to retrospectively test patient samples from Pfizer-sponsored clinical trials and demonstrated that the test is effective in identifying patients with ALK-positive NSCLC who may benefit from treatment with XALKORI® (crizotinib). Companion diagnostics (CDx) are tests designed to confirm the presence of a specific biomarker to assist physicians in selecting effective therapies for their patients, based on the individual characteristics of each person. Incorporating a companion diagnostic strategy into a drug development program may expedite the drug approval process and help generate more effective treatments with improved safety profiles for patients.
Halozyme Therapeutics, Inc., Ventana Medical Systems, Inc. Enter into Global Agreement to Collaboratively Develop Companion Diagnostic for Cancer Treatment
May 27 15
Halozyme Therapeutics, Inc. and Ventana Medical Systems, Inc. announced a global agreement to collaborate on the development of, and for Ventana to ultimately commercialize, a companion diagnostic assay for use with Halozyme's investigational new drug, PEGPH20. The Ventana assay will be used to identify high levels of hyaluronan (HA). HA is a glycosaminoglycan – a chain of natural sugars distributed throughout human tissue – that can accumulate around cancer cells. Halozyme has announced plans for rollout of a global phase 3 clinical study in 2016 targeting metastatic pancreatic cancer patients with high HA levels using its PEGPH20 in combination with ABRAXANE (nab-paclitaxel) and gemcitabine. Under the agreement, Ventana will develop an in vitro diagnostic (IVD), under design control, using Halozyme's proprietary HA binding protein, with the intent of submitting it for regulatory approval in the United States, Europe and other countries. This pharma collaboration is one of many at Ventana, where the Companion Diagnostics team is developing patient stratifying diagnostic tools that can help identify those individuals who are most likely to benefit from specific treatments. Companion diagnostics (CDx) are tests designed to confirm the presence of a specific biomarker to assist physicians in selecting effective therapies for their patients, based on the individual characteristics of each person. Incorporating a companion diagnostic strategy into a drug development program may expedite the drug approval process and help generate more effective treatments with improved safety profiles for patients.
Ventana Medical Systems, Inc. Enters into Master Collaboration Agreement with Astellas Pharma Inc
Apr 14 15
Ventana Medical Systems, Inc. announced it has entered into master collaboration agreement with Astellas Pharma Inc. to develop novel automated tissue diagnostics in support of therapeutic compounds in development. Initial projects related to this agreement will support early-stage clinical trials for the Astellas therapeutic compound ASP5878, a novel small-molecule fibroblast growth factor receptor (FGFR) inhibitor which has been shown to block the kinase activities of FGFR1, FGFR2, FGFR3 and FGFR4. Ventana will develop, in parallel, an immunohistochemistry (IHC) test identifying FGF19 in certain solid tumors.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|